Indeed, depending on the tumor genotype, about half to three quarters of patients with advanced GIST respond to treatment with anti-KIT/PDGFRA tyrosine kinase inhibitors (TKIs) including the first-line drug, imatinib mesylate (Novartis Pharmaceuticals, Switzerland). This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.